Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christoph Matthias Ahlers is active.

Publication


Featured researches published by Christoph Matthias Ahlers.


Journal of Clinical Oncology | 2015

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott N. Gettinger; Leora Horn; Leena Gandhi; David R. Spigel; Scott Antonia; Naiyer A. Rizvi; John D. Powderly; Rebecca S. Heist; Richard D. Carvajal; David M. Jackman; Lecia V. Sequist; David C. Smith; Philip D. Leming; David P. Carbone; Mary Pinder-Schenck; Suzanne L. Topalian; F. Stephen Hodi; Jeffrey A. Sosman; Mario Sznol; David F. McDermott; Drew M. Pardoll; Vindira Sankar; Christoph Matthias Ahlers; Mark E. Salvati; Jon M. Wigginton; Matthew D. Hellmann; Georgia Kollia; Ashok Kumar Gupta; Julie R. Brahmer

PURPOSE Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with expansion cohorts. We report overall survival (OS), response durability, and long-term safety in patients with non-small-cell lung cancer (NSCLC) receiving nivolumab in this trial. PATIENTS AND METHODS Patients (N = 129) with heavily pretreated advanced NSCLC received nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks in 8-week cycles for up to 96 weeks. Tumor burden was assessed by RECIST (version 1.0) after each cycle. RESULTS Median OS across doses was 9.9 months; 1-, 2-, and 3-year OS rates were 42%, 24%, and 18%, respectively, across doses and 56%, 42%, and 27%, respectively, at the 3-mg/kg dose (n = 37) chosen for further clinical development. Among 22 patients (17%) with objective responses, estimated median response duration was 17.0 months. An additional six patients (5%) had unconventional immune-pattern responses. Response rates were similar in squamous and nonsquamous NSCLC. Eighteen responding patients discontinued nivolumab for reasons other than progressive disease; nine (50%) of those had responses lasting > 9 months after their last dose. Grade 3 to 4 treatment-related adverse events occurred in 14% of patients. Three treatment-related deaths (2% of patients) occurred, each associated with pneumonitis. CONCLUSION Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC. Randomized clinical trials with nivolumab in advanced NSCLC are ongoing.


The Journal of Clinical Pharmacology | 2012

Food Increased the Bioavailability of BMS‐690514, an Orally Active EGFR/HER2/VEGF Receptor Kinase Inhibitor, in Healthy Subjects

Blisse Vakkalagadda; Jong-Soon Park; Christoph Matthias Ahlers; Stephanie M Dorizio; Teresa Has; Vikram Roongta; K. N. Heller; George Derbin; Steven Zhang

We studied the effect of food on pharmacokinetics, safety, and tolerability of BMS‐690514. Two open‐label, randomized, single‐dose, 2‐treatment, 2‐period crossover studies were performed in healthy subjects. In study 1 (N = 26), a single oral dose of BMS‐690514, 200 mg, was administered while fasting or after a high‐fat meal, and in study 2 (N = 17), a single oral dose of BMS‐690514, 200 mg, was administered while fasting or after a light meal. Compared with fasting, the adjusted geometric mean maximum observed plasma concentration (Cmax), area under the plasma concentration‐time curve from time zero to time of last quantifiable concentration (AUC0‐T), area under the plasma concentration‐time curve from time zero extrapolated to infinite time (AUCINF) of BMS‐690514 increased by 55%, 33%, and 34%, respectively, following a high‐fat meal (951 kcal, 52% fat) and by 41%, 20%, and 20%, respectively, following a light meal (336 kcal, 75% carbohydrate). BMS‐690514 was well tolerated in both studies. Most frequently occurring adverse events were diarrhea and acne in study 1 and rash, dry skin, and diarrhea in study 2. Systemic exposure of highly soluble BMS‐690514 was increased when given along with a meal, probably through inhibition of intestinal first‐pass metabolism and/or efflux transporters by food. These studies also demonstrated a tolerable safety profile of BMS‐690514 in the absence and presence of food.


Cancer Research | 2010

Abstract 3752: Folate receptor expression prevalence across multiple tumor types and concordance between matched primary and metastatic tumor pairs

Hewei Li; Qiuyan Wu; Guan Xing; Vic Teslenko; Jan M. Van Tornout; Christoph Matthias Ahlers; Fei Huang

Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Background: The human folate receptor (FR) is selectively overexpressed in a number of human epithelial malignancies, including ovarian, renal, and prostate cancers. Folate-conjugated therapies provide a strategy for targeting patients with FR expressing tumors. Identification of patients with FR expressing tumors is important to increase the opportunity for clinical benefit from folate conjugated therapies. The goals of this study are to determine the prevalence of FRα expression in various solid tumors, and to determine the concordance of FRα expression between primary and matched metastatic tumors. This concordance could help to determine if primary tumor samples would be suitable for assessing FR expression in metastatic tumors. Little information on this is currently available. Methods: FRα expression was analyzed by immunohistochemistry (IHC) in 339 primary tumors covering a wide range of human tumor types. Concordance of FRα status in 86 archived primary and matched metastatic breast, renal, endometrial and ovarian tumors was assessed by IHC. Results: FRα expression prevalence was moderate to high in primary tumors of lung (13/29; 45%), renal (66/115; 57%), colon (17/27; 63%), prostate (8/12; 67%) and ovarian (22/29; 76%). FRα expression frequency was found relatively low in breast tumor (26/127; 20%) which is consistent with previous reports. Furthermore, for the first time, we showed a good concordance (81.4%) of FRα expression between paired primary and metastatic ovarian, endometrial, renal and breast malignancies. Conclusions: FRα is frequently overexpressed in ovarian, prostate, colon and renal tumors, suggesting these tumor patients might benefit more from folate conjugated therapies. New findings from this study show that FRα expression is maintained in metastatic tumors, indicating the utility of archived primary tumor samples for determining the FR positivity of metastatic tumors in patients receiving a folate conjugated agent. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3752.


Journal of Clinical Oncology | 2010

A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.

Lillian L. Siu; Kyriakos P. Papadopoulos; Steven R. Alberts; R. Kirchoff-Ross; B. Vakkalagadda; Lixin Lang; Christoph Matthias Ahlers; Kelly L. Bennett; J. M. Van Tornout


Cancer Chemotherapy and Pharmacology | 2016

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70

Taofeek K. Owonikoko; Arif Hussain; Walter M. Stadler; David C. Smith; Harriet M. Kluger; Ana M. Molina; Parul Gulati; Aadhar Shah; Christoph Matthias Ahlers; Pina M. Cardarelli; Lewis J. Cohen


Journal of Clinical Oncology | 2017

A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL).

Taofeek K. Owonikoko; Arif Hussain; Walter M. Stadler; David C. Smith; Mario Sznol; Ana M. Molina; Parul Gulati; Aadhar Shah; Christoph Matthias Ahlers; Josephine M. Cardarelli; Lewis J. Cohen


Cancer Chemotherapy and Pharmacology | 2014

A phase I study of oral ixabepilone in patients with advanced solid tumors

John F. Deeken; John L. Marshall; Michael J. Pishvaian; Jimmy J. Hwang; Christoph Matthias Ahlers; Pamela L. Clemens; Susan M. Parker; Lisa Iacono; Patricia LoRusso


Journal of Clinical Oncology | 2013

An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).

Jeffrey A. Sosman; Salvador Martín-Algarra; Jedd D. Wolchok; William H. Sharfman; Shailender Bhatia; F. Stephen Hodi; Wen-Jen Hwu; Thomas F. Gajewski; Craig L. Slingluff; Howard L. Kaufman; Manish Gupta; Analia McGirr; Christine Horak; Christoph Matthias Ahlers; Jon M. Wigginton; Walter J. Urba


Journal of Clinical Oncology | 2017

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

Julie R. Brahmer; Leora Horn; Scott Antonia; David R. Spigel; Leena Gandhi; Lecia V. Sequist; Vindira Sankar; Christoph Matthias Ahlers; Jon M. Wigginton; Georgia Kollia; Ashok Kumar Gupta; Scott N. Gettinger


Journal of Clinical Oncology | 2017

Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.

Cariad Chester; Serena Chang; John F. Kurland; Idit Sagiv-Barfi; Debra K. Czerwinski; Amanda Rajapaksa; Erin Waller; Mohith Sadaram; Lori Richards; Lewis J. Cohen; Christoph Matthias Ahlers; Maria Jure-Kunkel; Holden T. Maecker; Ronald Levy; Holbrook Kohrt

Collaboration


Dive into the Christoph Matthias Ahlers's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David C. Smith

University of Rhode Island

View shared research outputs
Top Co-Authors

Avatar

Scott Antonia

University of South Florida

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge